Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Analgesia · Postoperative Pain · HRTX

Heron Therapeutics

Heron Therapeutics clinical programs — 18 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
100 Regency Forest Dr, Cary, North Carolina 27518, US HQ
1983 Founded
188 Employees
Public company Type
HRTX · NYSE Ticker
Company details
Status
Public
HQ
100 Regency Forest Dr, Cary, North Carolina 27518, US
Founded
1983
Employees
188
Programs
18
Drugs
17
Patents
46
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

Heron Therapeutics projects

18 ClinicalTrials.gov programs sponsored by Heron Therapeutics.

Heron Therapeutics has 18 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

18 programs

Clinical programs

  1. APF530

    Heron Therapeutics

    Chemotherapy-induced Nausea and Vomiting

    phase 3 small molecule completed

    1 trial

  2. APF530

    Heron Therapeutics

    Nausea and Vomiting

    phase 3 small molecule completed

    1 trial

  3. Aprepitant injectable emulsion

    Heron Therapeutics

    COVID-19

    phase 2 small molecule terminated

    1 trial

  4. B10 L-BPA Injection

    Heron Therapeutics

    Malignant Brain Tumors

    phase 2 small molecule active

    1 trial

  5. B10 L-BPA Injection

    Heron Therapeutics

    Meningioma

    phase 2 small molecule completed

    1 trial

  6. Bupivacaine HCI without epinephrine

    Heron Therapeutics

    Post-Operative Pain

    phase 2 small molecule completed

    1 trial

  7. Drug: B10 L-BPA Injection

    Heron Therapeutics

    Head and Neck Cancer

    phase 2 small molecule active

    1 trial

  8. GRANISETRON EXTENDED RELEASE INJECTION (GERSC)

    Heron Therapeutics

    Chemotherapy-induced Nausea and Vomiting

    phase 2 small molecule terminated

    1 trial

  9. HTX-011A

    Heron Therapeutics

    Postoperative Pain

    phase 2 small molecule completed

    1 trial

  10. HTX-011B

    Heron Therapeutics

    Postoperative Pain

    phase 2 small molecule completed

    1 trial

  11. HTX-034

    Heron Therapeutics

    Bunions

    phase 2 small molecule completed

    1 trial

  12. Bupivacaine HCl

    Heron Therapeutics

    Analgesia

    approved small molecule completed

    1 trial

  13. Bupivacaine Hydrochloride

    Heron Therapeutics

    Analgesia

    approved small molecule active

    1 trial

  14. Bupivacaine liposome injectable suspension

    Heron Therapeutics

    Analgesia

    approved small molecule completed

    1 trial

  15. HTX-011

    Heron Therapeutics

    Postoperative Pain

    approved small molecule completed

    8 trials

  16. HTX-011

    Heron Therapeutics

    Analgesia

    approved small molecule completed

    6 trials

  17. SUSTOL

    Heron Therapeutics

    Chemotherapy-Induced Nausea and Vomiting (CINV)

    approved small molecule active

    1 trial

  18. ZYNRELEF 200Mg-6Mg Extended-Release Solution

    Heron Therapeutics

    Post Operative Pain, Acute

    approved small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Heron Therapeutics have?

18 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.